Media

Here you will find our latest & archived press releases, stories and our corporate brand guidelines.

Press Releases

Press Release	Date
Sun Pharma reports Q2FY25 results	Oct 28, 2024
Sun Pharma Presents LEQSELVI at the 2024 Fall Clinical Dermatology Conference	Oct 25, 2024
WINLEVI poster presentations at 2024 Fall Clinical Dermatology Conference	Oct 25, 2024
Sun Pharma to announce Second quarter results on October 28, 2024	Oct 1, 2024
Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN	Oct 1, 2024
Sun Pharma Presents New Clinical Efficacy and Safety Data in Severe Dermatological Conditions at the 2024 European Academy of Dermatology and Venereology (EADV) Congress	Sept 26, 2024
Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain	Sept 06, 2024
Sun Pharma introduces a novel treatment, STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections	August 23, 2024
Sun Pharma reports Q1 FY25 Financial Press Release	August 01, 2024
U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata	July 26, 2024
Sun Pharma to announce first quarter results on August 01, 2024	July 16, 2024
Validation of Nidlegy™ Marketing Authorization Application Submission by EMA	July 04, 2024
Sun Pharma Launches #SecondBirthDate 2.0 Initiative with Sushmita Sen on National Doctors’ Day: Celebrating Real-life Heroes	July 01, 2024
Sun Pharma Completes Taro Merger	June 24, 2024
Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions	June 22, 2024
Sun Pharma signs non-exclusive patent licensing agreement with Takeda for introducing Novel Gastrointestinal Drug, Voltapraz (Vonoprazan) in India	June 21, 2024
Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis (OA)	June 14, 2024
Press Release Nidlegy™ Marketing Authorization Application Submitted to EMA	June 04, 2024
Press Release Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024	May 31, 2024
Taro Shareholders Approve Merger with Sun Pharma	May 23, 2024
Sun Pharma reports Q4 and full year FY24 Financial Press Release	May 22, 2024
Sun Pharma to announce fourth quarter results on May 22, 2024	May 15, 2024
Sun Pharmaceuticals announces approval of Winlevi^® in Australia	March 19, 2024
Sun Pharma included in S&P Global Sustainability Yearbook 2024	February 12, 2024
Sun Pharma reports Q3FY24 results	January 31, 2024
Taro Announces Merger Agreement with Sun Pharma	January 18, 2024
Sun Pharma and Bayer sign marketing and distribution agreement for second brand of Finerenone in India	January 17, 2024
Sun Pharma to announce third quarter results on January 31, 2024	January 16, 2024

Press Release	Date
Q2 FY24 Financial Press Release	November 1, 2023
Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat in India	October 30, 2023
Sun Pharma to announce second quarter results on November 01, 2023	October 17, 2023
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma	October 16, 2023
CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis® (cyclosporine ophthalmic emulsion) 0.05%	October 12, 2023
Sun Pharma Announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib	October 6, 2023
Sun Pharma Canada Launches ^PRWINLEVI® (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne	September 27, 2023
Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India	September 14, 2023
Sun Pharma to announce first quarter results on August 03, 2023	July 17, 2023
Sun Pharma launches nationwide initiative, #SecondBirthDate on National Doctor’s Day	July 1, 2023
ADA GL0034 Data Release	June 24, 2023
Sun Pharma Announces Health Canada Approval of PRWINLEVI® (clascoterone cream 1%) for Topical Treatment of Acne	June 19, 2023
Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis	May 30, 2023
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand	May 30, 2023
Q4 FY23 Financial Press Release	May 26, 2023
Sun Pharma to announce fourth quarter results on May 26, 2023	May 26, 2023
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India	April 25, 2023
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study	March 22, 2023
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata	March 18, 2023
Sun Pharma completes acquisition of Concert Pharmaceuticals	March 06, 2023
Sun Pharma Announces US FDA Approval for Generic Lenalidomide Capsules	February 10, 2023
Q3 FY23 Financial Press Release	January 31, 2023
Sun Pharma acquires Disperzyme® and Phlogam® brands to strengthen its anti-inflammatory portfolio	January 30, 2023
Sun Pharma Launches SEZABY™ (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures	January 25, 2023
Sun Pharma to Acquire Concert Pharmaceuticals Inc	January 19, 2023
Sun Pharma to announce third quarter results on January 31, 2023	January 17, 2023
Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer with a unique Patient Assistance Program	January 11, 2023

Press Release	Date
Sun Pharma is Great Place To Work® Certified™ in India	December 21, 2022
SEZABY™ (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures	November 18, 2022
Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US	November 09, 2022
Q2 FY23 Financial Press Release	November 01, 2022
“Apni Body Ki Suno” says the latest campaign of Sun Pharma’s Revital H	October 14, 2022
Sun Pharma to announce second quarter results on November 01, 2022	October 11, 2022
Sun Pharma Chairman, Israel Makov to retire on completion of term	August 03, 2022
Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia	July 26, 2022
Sun Pharma to announce first quarter results on July 29, 2022	July 13, 2022
Q4 FY22 Financial Press Release	May 30, 2022
Sun Pharma Acquires Uractiv™ Portfolio from Fiterman Pharma in Romania	May 27, 2022
Sun Pharma to launch Brillo®, a first-in-class oral lipid-lowering drug in India	May 18, 2022
Sun Pharma to announce fourth quarter results on May 30, 2022	May 16, 2022
Sun Pharma Announces US FDA Approval for Generic Mesalamine Extended Release Capsules	May 12, 2022
Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck	March 30, 2022
Intimation under Regulation 30- 29th March, 2022	March 29, 2022
Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting	March 25, 2022
Q3 FY22 Financial Press Release	January 31, 2022
Sun Pharma launches CEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada	January 27, 2022
Sun Pharma to announce third quarter results on January 31, 2022	January 18, 2022

Press Release	Date
Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India	December 28, 2021
Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection	December 15, 2021
Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the brand name Molxvir® in India	November 11, 2021
Q2 FY22 Financial Press Release	November 2, 2021
Sun Pharma Announces Availability of WINLEVI® (clascoterone) cream 1% in the U.S. for Topical Treatment of Acne Vulgaris	November 1, 2021
Sun Pharma’s ILUMYA™ (tildrakizumab injection) now available to help Canadians living with moderate-to-severe plaque psoriasis	October 28, 2021
Sun Pharma to announce second quarter results on November 02, 2021	October 19, 2021
Sun Pharma launches Chericof® 12 in India, a novel formulation that provides relief from cough for up to 12 hours	September 28, 2021
Sun Pharma forays into Nutrition Bar segment with the launch of Revital NXT	September 08, 2021
Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi® (clascoterone cream 1%) agreement	August 31, 2021
Q1 FY22 Financial Press Release	July 30, 2021
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada	July 26, 2021
Sun Pharma to announce first quarter results on July 30, 2021	July 16, 2021
Sun Pharma launches ‘Sunkalp’ on the occasion of National Doctors’ Day	July 01, 2021
Press Release Pharma Majors Collaborate for Clinical Trial of Anti Viral Drug Molnupiravir for COVID-19	June 29, 2021
Press Release Settlement of Patent Litigation for Generic Revlimid in US	June 22, 2021
Sun Pharma and Ferring Pharmaceuticals enter into licensing agreement for introducing CARITEC® in India	June 02, 2021
Q4 FY21 Financial Press Release	May 27, 2021
Sun Pharma Q4 FY21 financial result on May 27, 2021	May 12, 2021
Sun Pharma signs voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in India	May 10, 2021
Sun Pharma Launches Website for its Long Term Care Portfolio in the US	February 25, 2021
Sun Pharma to introduce complete range of Brivaracetam at an affordable price for epilepsy treatment in India	February 23, 2021
SPIL Q3FY21 Financials Results	January 29, 2021
Sun Pharma’s financials for Q3 and nine month period ending December 31, 2020	January 29, 2021
Sun Pharma to announce third quarter results on January 29, 2021	January 04, 2021
Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque Psoriasis	January 04, 2021

Press Release	Date
FY21 Q2 Financial Press Release	November 03, 2020
FY21 Q2 Financial Results	November 03, 2020
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® in Patients with Moderate-to-Severe Plaque Psoriasis	October 31, 2020
Sun Pharma to announce Second quarter results on November 03, 2020	October 22, 2020
Press Release Sun Pharma announces the launch of ILUMYA for treatment of plaque psoriasis in Japan	September 23, 2020
FY21 Q1 Financial Result - Transcript	August 26, 2020
Sun Pharma launches FluGuard® (Favipiravir) in India at Rs. 35 per tablet	August 04, 2020
FY21 Q1 Financial Press Release	July 31, 2020
FY21 Q1 Financial Results	July 31, 2020
Sun Pharma launches ‘Thank you Doctor’ campaign	July 09, 2020
FY20 Q4 Financial Result - Transcript	July 06, 2020
Sun Pharma announces Japan MHLW approval of ILUMYA for the treatment of Plaque Psoriasis	June 29, 2020
Sun Pharma Announces Pre-Clinical Data on GL0034	June 24, 2020
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA™ for Middle East & North Africa regions	June 15, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA TM	June 13, 2020
Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer	June 13, 2020
Sun Pharma initiates Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patients	June 05, 2020
Sun Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid 19 patients	May 29, 2020
Sun Pharma and SPARC enter into a worldwide license agreement for SCD 044	May 28, 2020
Sun Pharma Q4FY20 Financial Results	May 27, 2020
FY20 Q4 Financial Press Release	May 27, 2020
FY20 Q4 Financial Results	May 27, 2020
Sun Pharma to announce fourth quarter results on May 27, 2020	May 19, 2020
FY20 Q3 Financial Result - Transcript	April 09, 2020
Sun Pharma Commits Donation of Medicines and Hand Sanitizers to Support India’s COVID-19 Pandemic Response	March 27, 2020
SPII Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment	March 27, 2020
FY20 Q3 Financial Results	February 06, 2020
FY20 Q3 Financial Press Release	February 06, 2020
Sun Pharma Introduces ABSORICA LD™ Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.	February 04, 2020
Sun Pharma to announce third quarter results on 06 February 2020	January 20, 2020
Sun Pharma and Rockwell Medical enter into licensing agreement for Triferic in India	January 15, 2020

Press Release	Date
FY20 Q2 Financial Result - Transcript	December 10, 2019
FY20 Q2 Financial Results	November 07, 2019
FY20 Q2 Financial Press Release	November 07, 2019
Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in China	November 06, 2019
Sun Pharma to announce second quarter results on 07 November 2019	October 24, 2019
Sun Pharma Launches Drizalma Sprinkle in the US	October 16, 2019
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the US	October 14, 2019
Malaria Elimination Programme Receives Mahatma Award for Social Good	October 10, 2019
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA	October 09, 2019
FY20 Q1 Financial Result - Transcript	October 03, 2019
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland China	August 16, 2019
Sun Pharma and China Medical System Holdings Enter into Licensing Agreement for Generic Products in Mainland ChinaSun Pharma Announces Licensing Agreement With CSIR-IICT	August 14, 2019
FY20 Q1 Financial Results	August 13, 2019
FY20 Q1 Financial Press Release	August 13, 2019
Sun Pharma to announce first quarter results on August 13, 2019	August 05, 2019
Sun Pharma Announces Regulatory Filing of Tildrakizumab in Japan	August 01, 2019
Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing	July 15, 2019
Sun Pharma and China Medical System Holdings enter into a License Agreement for Tildrakizumab in Greater China	June 27, 2019
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China	June 27, 2019
Late Breaking Phase 2 Data Showing Potential of ILUMYA for Psoriatic Arthritis	June 14, 2019
FY19 Q4 Financial Results	May 28, 2019
FY19 Q4 Financial Press Release	May 28, 2019
Sun Pharma to announce fourth quarter results on May 28, 2019	May 14, 2019
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.	April 08, 2019
FY19 Q3 Financial Result - Transcript	March 08, 2019
ILUMYA 3 Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis	March 01, 2019
FY19 Q3 Financial Press Release	February 12, 2019
Sun Pharma Q3 FY19 financial result on 12 February 2019	January 28, 2019
Press Release Sun Pharma Investor Update	January 22, 2019

Press Release	Date
Investor Update Call Transcript	December 27, 2018
DUSA Pharmaceuticals, Inc. Awarded Preliminary Injunctive Relief Prohibiting Biofrontera From Using Its Trade Secrets	December 26, 2018
Clarification on recent media reports	December 03, 2018
Sun Pharma Announces US FDA Approval For Generic Ganirelix Acetate Injection	December 03, 2018
Sun Pharma to hold an Investor Update Call on 03 December 2018	December 03, 2018
Sun Pharma to acquire Pola Pharma in Japan	November 26, 2018
FY19 Q2 Financial Result - Transcript	November 20, 2018
FY19 Q2 Financial Press Release	November 13, 2018
Sun Pharma Announces the Availability of ILUMYA in the United States	October 23, 2018
Sun Pharma to announce second quarter results on 13 November 2018	October 23, 2018
Sun Pharma announces Australian TGA approval of ILUMYA	September 21, 2018
Sun Pharma Announces Receipt of European Commission Approval For ILUMETRI	September 18, 2018
Sun Pharma and SPARC Announce US FDA Approval of XELPROS	September 14, 2018
Clarification to Stock Exchanges on Mohali facility	September 11, 2018
Clarification to Stock Exchanges on news regarding Halol facility	September 07, 2018
FY19 Q1 Financial Result - Transcript	September 04, 2018
Sun Pharma launches Volini Maxx, India’s Strongest Pain Relief Spray	August 29, 2018
Sun Pharma Announces USFDA Approval of CEQUA to Treat Dry Eye Disease	August 16, 2018
FY19 Q1 Financial Press Release	August 14, 2018
Sun Pharma Launches Novel Drug Kapspargo Sprinkle™ in USA	August 06, 2018
Sun Pharma to announce first quarter results on 14 August 2018	July 27, 2018
Sun Pharma Announces Launch of Generic Glumetza® Tablets in US	July 25, 2018
Sun Pharma Announces USFDA Approval of INFUGEM Injection	July 18, 2018
DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc.	July 11, 2018
Sun Pharma signs Akshay Kumar as Revital H Brand Ambassador	July 09, 2018
Sun Pharma receives EIR for Halol facility	June 12, 2018
Clarification on news regarding Halol	June 08, 2018
FY18 Q4 Financial Result - Transcript	June 08, 2018
FY18 Q4 Financial Press Release	May 25, 2018
Sun Pharma Announces USFDA Approval of YONSA	May 23, 2018
Sun Pharma Announces US Launch of Authorized Generic for Welchol Tablets	May 17, 2018
Sun Pharma to announce fourth quarter results on 25 May 2018	May 11, 2018
Sun Pharma CHC enters anti fungal powder OTC category with ABZORB	April 30, 2018
FDEC First Year Report of Malaria Elimination Demonstration Project (MEDP)	March 23, 2018
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn)	March 21, 2018
ILUMYA™ U.S. Prescribing Information	March 21, 2018
ILUMYA™ U.S. Medication Guide	March 21, 2018
FY18 Q3 Financial Press Release	February 14, 2018
Sun Pharma Science Foundation's Annual Conference and Research Awards Presentation Ceremony	February 13, 2018
Sun Pharma to announce third quarter results on February 14, 2018	February 02, 2018
Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US	January 16, 2018

Press Release	Date
Sun Pharma Announces US FDA Acceptance of NDA for OTX-101	December 27, 2017
FY18 Q2 Financial Result - Transcript	December 02, 2017
Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet®	November 24, 2017
FY18 Q2 Financial Press Release	November 14, 2017
Sun Pharma to announce second quarter results on November 14, 2017	October 31, 2017
Sun Pharma announces US FDA approval for generic Coreg CR®	October 26, 2017
Sun Pharma Odomzo® (Sonidegib) New Label Approval	September 20, 2017
FY18 Q1 Financial Result - Transcript	September 15, 2017
FY18 Q1 Financial Press Release	August 11, 2017
Sun Pharma to announce first quarter results on August 11, 2017	July 26, 2017
Sun Pharma and Samsung BioLogics announce strategic manufacturing tie up for Tildrakizumab	July 04, 2017
Sun Pharma and NIV sign agreement to fight Zika, Chikungunya and Dengue	June 27, 2017
US FDA approval for generic Zetia® tablets	June 13, 2017
FY17 Q4 Financial Result - Transcript	June 13, 2017
FY17 Q4 Financial Press Release	May 26, 2017
US FDA Filing Acceptance of Biologics License Application For Tildrakizumab	May 24, 2017
Sun Pharma to announce fourth quarter results on May 26, 2017	May 15, 2017
Sun Pharma Science Foundation recognizes Indian scientists & young research scholars	April 28, 2017
FDEC commences roll-out of Malaria demonstration project	April 25, 2017
Sun Pharma Science Foundation Media Invitation	April 25, 2017
Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe	March 24, 2017
Update on Mohali Facility	March 14, 2017
Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting	March 01, 2017
FY17 Q3 Financial Result - Transcript	February 27, 2017
FY17 Q3 Financial Press Release	February 14, 2017
Sun Pharma Q3 FY17 financial result on February 14, 2017	January 31, 2017
Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye	January 04, 2017

Press Release	Date
Sun Pharma & Moebius Medical sign deal to develop novel liposomal non-opiod pain product for osteoarthritis	December 12, 2016
FY17 Q2 Financial Result - Transcript	November 30, 2016
Sun Pharma launches first branded ophthalmic product, BromSite in USA	November 28, 2016
Sun Pharma to acquire Biosintez in Russia	November 23, 2016
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- English Press Release	November 15, 2016
ICMR, Govt of MP and FDEC-India sign tri-party agreement to launch Malaria Free India demonstration project in Mandla district of Madhya Pradesh- Hindi Press Release	November 15, 2016
FY17 Q2 Financial Press Release	November 10, 2016
Sun Pharma Announces US Launch of Authorized Generics for Olmesartan	October 27, 2016
Sun Pharma Q2 FY17 financial result on November 10, 2016	October 26, 2016
Sun Pharma to Acquire Ocular Technologies	October 26, 2016
Sun Pharma & ICGEB announce new exclusive collaboration to develop novel dengue vaccine for India & Global markets	October 19, 2016
Revital H Woman launches ‘Healthy Conversations’ initiative	October 03, 2016
Sun Pharma to Announce Late-Breaking Results for Tildrakizumab	October 01, 2016
Sun Pharma announces distribution alliance with Mitsubishi Tanabe Pharma Corporation in Japan	September 06, 2016
FY17 Q1 Financial Result - Transcript	August 29, 2016
FY17 Q1 Financial Press Release	August 12, 2016
Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USA	August 08, 2016
Sun Pharma announces US FDA approval for generic Glumetza®	August 02, 2016
Sun Pharma to announce first quarter results on August 12, 2016	August 01, 2016
Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis	July 27, 2016
Sun Pharma announces US FDA approval for generic Crestor®	July 20, 2016
SPARC licenses Elepsia XR to Sun Pharma	July 18, 2016
Sun Pharma launches Gemcitabine InfuSMART	July 11, 2016
Sun Pharma Announces Buyback of Equity Shares	June 23, 2016
FY16 Q4 Financial Result - Transcript	June 10, 2016
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-Press Release	June 08, 2016
Sun Pharma focuses on dermatology as additional engine of growth for GCH business-Factsheet	June 08, 2016
Press Conference Invitation	June 06, 2016
Sun Pharma announces divestment of US manufacturing units	June 04, 2016
FY16 Q4 Financial Press Release	May 30, 2016
Sun Pharma to announce fourth quarter results on May 30, 2016	May 19, 2016
Sun Pharma leverages mobile technology to boost treatment compliance amongst asthma patients	May 09, 2016
Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis	May 04, 2016
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue	May 04, 2016
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue - Endorsements	May 04, 2016
ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue -Dengue Factsheet	May 04, 2016
Media Invitation - Signing of Novel Drug Development Agreement, May 4, 2016	April 29, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Press Release- Malaria Free India	April 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India public-private-partnership receives global recognition	April 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Free India Blue Print	April 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Malaria Factsheet	April 25, 2016
ICMR, MoHFW, GoI, GoMP and Sun Pharma announce Public-Private-Partnership for Malaria Free India - Spokesperson Bios	April 25, 2016
Press Conference Invitation, April 25, New Delhi	April 21, 2016
Sun Pharma Receives USFDA Approval For BromSite™	April 09, 2016
Sun Pharma enters Japanese prescription market	March 29, 2016
Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes	March 23, 2016
Video Release - Digital launch of Pepmelt antacid campaign	March 11, 2016
Note on Digital launch of Pepmelt antacid campaign	March 11, 2016
Sun Pharma Consumer Healthcare Business enhances presence in digestive care	March 11, 2016
Sun Pharma Global Consumer Healthcare signs Indian cricket captain MS Dhoni as Revital H brand ambassador	March 08, 2016
FY16 Q3 Earnings Call Transcript	February 26, 2016
FY16 Q3 Financial Press Release	February 12, 2016
Sun Pharma launches Imatinib Mesylate in USA	February 01, 2016
Sun Pharma to announce third quarter results on February 12, 2016	January 30, 2016
Revital H announces association with Patna Pirates, Kabbadi Team as Official Health Partner	January 27, 2016
Transcript - Update on Halol facility	January 04, 2016

Press Release	Date
Sun Pharma receives Warning Letter for Halol facility	December 19, 2015
Sun Pharma announces divestment of US manufacturing unit	December 14, 2015
Sun Pharma announces research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies	December 10, 2015
Sun Pharma announces US FDA approval for generic Gleevec®	December 04, 2015
Sun Pharma announces its association with World Champion Snowboarder Kelly Clark for Absorica®	December 02, 2015
FY16 Q2 Earnings Call Transcript	November 27, 2015
FY16 Q2 Financial Press Release	November 07, 2015
Sun Pharma Successfully Acquires InSite Vision	November 03, 2015
Volini announces Sania Mirza and Sunil Chhetri as brand ambassadors	November 03, 2015
Sun Pharma completes tender offer for InSite Vision	October 28, 2015
Sun Pharma Q2 & H1 FY16 financial results on November 07, 2015	October 26, 2015
Sun Pharma announces Absorica patent litigation settlement	October 05, 2015
Sun Pharma commences Tender Offer for Acquisition of InSite Vision	September 29, 2015
Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy	September 19, 2015
Sun Pharma to acquire InSite Vision	September 15, 2015
Sun Pharma announces successful completion of Opiates business acquisition in Australia	September 01, 2015
FY16 Q1 Earnings Call Transcript	August 25, 2015
Sun Pharma announces US FDA approval for Ximino	August 19, 2015
FY16 Q1 Financial Press Release	August 11, 2015
Sun Pharma to announce first quarter results on August 11, 2015	July 29, 2015
Transcript - Sun Pharma Business Update	July 24, 2015
Sun Pharma provides business update	July 20, 2015
SPARC Licenses XelprosTM (Latanoprost BAK-free) to Sun Pharma	June 09, 2015
Sun Pharma and AstraZeneca enter into distribution agreement for ticagrelor in India	June 02, 2015
Sun Pharma to announce fourth quarter FY15 results on May 29, 2015	May 15, 2015
Sun Pharma and the Technion form Research Collaboration to Develop New Class of Oncology Drugs	April 15, 2015
Sun Pharma announces closure of merger deal with Ranbaxy	March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Sun Pharma	March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Investor Relations Presentation	March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Factsheet	March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Profile of Chairman & MD	March 25, 2015
Sun Pharma announces closure of merger deal with Ranbaxy- Growing Together Film	March 25, 2015
Press Conference Webcast: Sun Pharma - Ranbaxy Merger	March 25, 2015
Sun Pharma to buy GSK’s Opiates business in Australia	March 03, 2015
FY15 Q3 Earning Call Transcript	February 24, 2015
Press Release SPIL Financials Q3 FY15	February 14, 2015
Sun Pharma to announce third quarter results on February 14, 2015	February 09, 2015
Sun Pharma receives US FTC clearance for Ranbaxy acquisition	February 02, 2015

Press Release	Date
CCI approves Ranbaxy acquisition by Sun Pharma	December 08, 2014
Sun Pharma to announce second quarter results on November 13, 2014	October 30, 2014
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab	September 17, 2014
Form IV contained in Schedule II to the Combination Regulations under Sec 29(2) of Competition Act, 2002 (as amended)	September 04, 2014
Q1 FY15 Earnings Call Transcript	August 23, 2014
Q1 FY15 Financial Press Release	August 12, 2014
Sun Pharma to announce first quarter results on August 12, 2014	July 30, 2014
Sun Pharma acquires Pharmalucence	July 16, 2014
Q4 FY14 Financial Press Release	May 29, 2014
Sun Pharma to announce Q4 and FY14 results on May 29, 2014	May 16, 2014
Sun Pharma announces settlement of litigation for generic Gleevec® in US	May 15, 2014
Sun Pharma announces manufacturing consolidation	May 02, 2014
Transcript Sun Pharma - Ranbaxy Merger Conference Call	April 16, 2014
Clarification on Silverstreet Investment in Ranbaxy	April 09, 2014
Investor Presentation: Sun Pharma & Ranbaxy merger	April 07, 2014
Sun Pharma to acquire Ranbaxy in a US$ 4 billion landmark transaction	April 06, 2014
Import Alert for Karkhadi unit from US FDA	March 13, 2014
FY14 Q3 Earnings call transcript	February 25, 2014
Rekha Sethi appointed as an additional independent director of Sun Pharma Board	February 13, 2014
FY14 Q3 Financial Press Release	February 13, 2014
Sun Pharma announces US FDA approval for generic Temodar®	February 13, 2014
Sun Pharma to announce third quarter results on February 13, 2014	January 29, 2014

Press Release	Date
Sun Pharma announces US FDA approval for generic Cymbalta®	December 12, 2013
FY14 Q2 Earnings call transcript	November 22, 2013
FY14 Q2 Financial Press Release	November 13, 2013
Sun Pharma to announce second quarter results on November 13, 2013	October 28, 2013
Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases	October 01, 2013
Sun Pharma announces USFDA approval for generic Prevacid®	September 14, 2013
FY14 Q1 Financial Press Release	August 09, 2013
Sun Pharma to announce first quarter results on August 09, 2013	July 23, 2013
Sun Pharma announces USFDA approval for generic Prandin®	July 12, 2013
Sun Pharma settles generic Protonix® litigation	June 12, 2013
FY13 Q4 Earnings Call Transcript	June 12, 2013
Sun Pharma announces USFDA approval for generic Depo®-Testosterone Injection	June 04, 2013
Sun Pharma Announces 1:1 Bonus	May 28, 2013
Sun Pharma reports strong performance	May 28, 2013
Sun Pharma to announce Q4 and FY13 results on May 28, 2013	May 17, 2013
Sun Pharma and Taro Announce Termination of Proposed Transaction	February 08, 2013
Sun Pharma announces USFDA approval for generic Doxil®	February 05, 2013
Sun Pharma to announce third quarter results on February 08, 2013	January 25, 2013

Press Release	Date
Successful acquisition of DUSA Pharmaceuticals, Inc.U.S.A.by our subsidiary	December 20, 2012
Sun Pharma acquires URL generic business from Takeda	December 17, 2012
Sun Pharma to acquire DUSA Pharmaceuticals, Inc.	November 08, 2012
Sun Pharma to announce second quarter results on November 08, 2012	October 22, 2012
Sun Pharma to take Taro Private	August 13, 2012
Sun Pharma to announce first quarter results on August 10, 2012	July 30, 2012
Israel Makov appointed chairman of Sun Pharma Board	May 29, 2012
Sun Pharma announces USFDA approval for generic Astelin® Nasal Spray	May 24, 2012
Sun Pharma to announce Q4 and FY12 results on May 29, 2012	May 15, 2012
Sun Pharma announces USFDA approval for generic Zyprexa® tablets	April 24, 2012
Favorable Ruling by United States Supreme Court on Prandin® Litigation	April 18, 2012
Sun Pharma announces USFDA approval for generic Seroquel® tablets	March 28, 2012
Sun Pharma announces USFDA approval for generic Zyprexa Zydis® tablets	February 29, 2012
Sun Pharma: An update on generic Protonix® litigation	February 15, 2012
Sun Pharma to announce Q3 FY12 results on February 13, 2012	January 31, 2012

Press Release	Date
Sun Pharma announces USFDA approval for generic Ultram® ER tablets	December 09, 2011
Sun Pharma to announce Q2 FY12 results on November 13, 2011	November 03, 2011
Sun Pharma announces USFDA approval for generic Cardizem CD®	October 31, 2011
Sun Pharma subsidiary resolves USFDA warning letter	September 19, 2011
Sun Pharma announces USFDA tentative approval for generic Plavix® tablets	July 29, 2011
Sun Pharma to announce Q1 FY12 results on July 28, 2011	July 20, 2011
Sun Pharma announces USFDA approval for generic Uroxatral® ER tablets Company gets 180 day marketing exclusivity on first-to-file ANDA with para IV certification	July 19, 2011
Sun Pharma announces USFDA approval for generic Imitrex® injection	June 21, 2011
Sun Pharma to announce Q4 and FY11 financial results on May 28, 2011	May 14, 2011
Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection	May 04, 2011
Call Transcript: Sun Pharma & Merck JV announcement	April 20, 2011
Sun Pharma and Merck Establish joint venture to develop and commercialize novel formulations and combinations of medicines	April 11, 2011
Sun Pharma announces USFDA approval for generic Razadyne® ER	February 03, 2011
Sun Pharma to announce Q3FY11 results on Jan 31, 2011	January 18, 2011

Press Release	Date
Sun Pharma announces USFDA tentative approval for generic Boniva®	December 30, 2010
Sun Pharma announces USFDA tentative approval for generic Aricept®	November 30, 2010
Sun Pharma announces USFDA tentative approval for generic Cymbalta®	November 24, 2010
Sun Pharma announces USFDA approval for generic Diltiazem ER®	November 18, 2010
Sun Pharma announces USFDA approval for generic Clarinex®	November 18, 2010
Sun Pharma announces USFDA tentative approval for generic Stalevo®	October 01, 2010
Sun Pharma announces USFDA tentative approval for generic Crestor®	September 29, 2010
Sun Pharma announces expiration of subsequent offering period	September 29, 2010
Sun Pharma announces USFDA tentative approval for generic Rilutek®	September 28, 2010
Sun Pharma acquires controlling stake in Taro	September 21, 2010
Sun Pharmaceutical announces expiration of offer for Taro	September 15, 2010
Supreme court of Israel rules in favor of Sun Pharma	September 07, 2010
Sun Pharma announces USFDA approval for generic Strattera® Capsules	August 31, 2010
Sun Pharma subsidiary receives warning letter from USFDA	August 31, 2010
Sun Pharma announces USFDA approval for generic Venlafaxine ER® Tablets	August 19, 2010
US appeals court rules Gemzar® patent invalid	July 29, 2010
Sun Pharma: an update on generic Protonix litigation®	July 17, 2010
Sun Pharma announces USFDA approval for generic Flomax®	July 16, 2010
US district court rules in favor of Sun Pharmaceutical dismisses all of Taro's claims	July 15, 2010
Sun Pharma to announce Q1FY11 results on July 28, 2010	July 13, 2010
Sun Pharma: an update on generic Eloxatin® injection	June 26, 2010
Sun Pharma settles litigation over generic StalevoÂ® and Comtan®	June 22, 2010
Sun Pharma announces USFDA approval for generic Optivar®	June 21, 2010
Sun Pharma announces USFDA approval for generic Xanax® Tablets	June 18, 2010
Sun Pharma announces USFDA approval for generic KeppraÂ® Injection, levetiracetam® injection	June 17, 2010
Sun Pharma: an update on generic Protonix® litigation	April 24, 2010
Sun Pharma announces USFDA tentative approval for generic Namenda® tablets	April 10, 2010
Sun Pharma announces USFDA approval for generic Wellbutrin® SR extended release tablets	April 08, 2010
Sun Pharma announces USFDA approval for generic Prometh® syrup	March 18, 2010
Sun Pharma sends letter to directors of Taro	January 11, 2010

Press Release	Date
Generic Eloxatin® and Imitrex® approval: shares 180-day marketing drug exclusivity for generic Eloxatin®	August 11, 2009
Sun Pharma signs agreement with MedImmune for generic Ethyol®	August 03, 2009
Sun Pharma to license key Escitalopram® patent applications to Lundbeck®	July 10, 2009
Sun Pharma announces USFDA approval for generic Casodex® tablets	July 07, 2009
Conference call transcript - FDA seizure at Caraco, June 2009s	July 02, 2009
Sun Pharma announces USFDA tentative approval for generic Optivar®	July 02, 2009
Sun Pharma to hold conference call on June 27, 2009	June 26, 2009
Sun Pharma announces USFDA approval for generic Accupril® tablets	June 19, 2009
Sun Pharma to announce FY09 results on May 30. Earnings call on June 1, 2009.	May 18, 2009
Sun Pharma announces USFDA tentative approval for generic Uroxatral® extended release tablets.	May 07, 2009
Sun Pharma announces USFDA approval to market generic Roxicodone® tablets.	April 13, 2009
Sun Pharma announces USFDA approval to market generic Topamax® tablets	March 28, 2009
Sun Pharma extends tender offer for Taro to April 3, 2009	March 20, 2009
Sun Pharma extends tender offer for Taro to Mar 20, 2009	March 06, 2009
Sun Pharma extends tender offer for Taro to March 6, 2009	January 29, 2009
Sun Pharma Q3 results on Jan 30; conf call on Jan 31	January 24, 2009
Sun Pharmaceutical extends tender offer for Taro to January 30, 2009	January 07, 2009
Sun Pharma receives USFDA approvals for 4 generic products; company receives its first controlled substance product approval	January 07, 2009

Press Release	Date
Sun Pharmaceutical extends tender offer for Taro December 19, 2008	January 9, 2009
Sun Pharma update on ANDA for generic Effexor XR: USFDA grants Osmotica's citizen petition	November 27, 2008
Sun Pharma subsidiary acquires 100% of Chattem Chemicals, Inc. a US based DEA registered narcotic API importer & producer	November 25, 2008
Sun Pharmaceutical extends tender offer for Taro to Dec 19, 2008	November 07, 2008
Sun Pharmaceutical announces USFDA approval to market generic Sinemet® tablets	November 05, 2008
Sun Pharma to announce Q2 and H1 2008-09 results on Oct 25, 2008	October 15, 2008
Sun Pharma extends tender offer for Taro	October 03, 2008
Sun Pharma announces USFDA approval to market generic Paraplatin® injection	September 23, 2008
Sun Pharma gets USFDA approval for generic Fosamax® tablets	September 12, 2008
Sun Pharmaceutical extends tender offer for Taro	September 03, 2008
Sun to file amendment to tender offer for Taro waiving certain conditions	August 27, 2008
Tel-Aviv court rules in favor of Sun Pharmaceutical; no special tender offer neccessary in Taro offer	August 27, 2008
Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro’s Irish Subsidiary	August 25, 2008
Sun Pharma announces US FTC clearance	August 14, 2008
Sun Pharma gets USFDA approval for generic Depakote® delayed release tablets	July 30, 2008
Sun Pharma reaffirms commitment to Taro facilities and employees	July 28, 2008
Sun Pharma extends tender offer for Taro	July 14, 2008
Sun Pharma commences tender offer for Taro shares	June 30, 2008
Sun Pharma exercises its options to acquire the shares of the controlling shareholders of Taro Pharma	June 26, 2008
Sun Pharma comments on Taro's potential sale of its Irish operations	June 05, 2008
Sun Pharma responds to Taros purported termination of merger agreement	May 29, 2008
Sun Pharma receives notice for termination of merger from Taro	May 28, 2008
Q4 2007-08 results on 30 May, 2008; earnings call on 30 May, 2008 at 6:30 PM IST	May 17, 2008
Sun Pharmaceutical announces launch of generic Ethyol ® (180 days exclusivity)	March 31, 2008
Sun Pharmaceutical announces USFDA approval to market generic Tessalon ®	March 21, 2008
Sun Pharmaceutical announces USFDA approval to market generic Cerebyx ®	March 19, 2008
Sun Pharmaceutical announces USFDA approval to market generic Ethyol ® (With 180 day marketing exclusivity)	March 15, 2008
Sun Pharma gets USFDA tentative approval for generic Gemzar ® injection	March 05, 2008
Sun Pharma gets USFDA approval to market generic Demadex ® Tablets	February 27, 2008
Sun Pharma buys additional 9.4% stake in Taro Pharma from Brandes	February 19, 2008
Sun Pharma gets USFDA tentative approval for generic Depakote ® delayed release tablets	February 14, 2008
Sun Pharma launches generic Protonix ® Tablets	January 30, 2008
Sun Pharma Q3 2007-08 results on 30 Jan, 2008; earnings call on January 31, 2008 on 10:00 am IST	January 16, 2008

Press Release	Date
Sun Pharma announces settlement of litigation over generic Exelon®	December 06, 2007
Sun Pharma announces USFDA approval to market generic Exelon® Capsules	October 23, 2007
Sun Pharma receives will-not-sue covenant on generic Effexor XR ® ANDA	October 16, 2007
Sun Pharma Q2 2007-08 results on Oct 25, 2007; earnings call on Oct 26 at 10 am IST	October 09, 2007
Sun Pharma announces USFDA approval to market generic Trileptal® Tablets, 180 day marketing exclusivity	October 10, 2007
Sun Pharma announces USFDA approval to market generic Protonix Tablets - Company gets its first 180 day marketing exclusivity on a first-to-file ANDA with para IV certification	September 11, 2007
USFDA grants tentative approval for Sun Pharma's ANDA for Galantamine tablets	August 30, 2007
Sun Pharma announces USFDA approval for Sinemet CR, an extended release version of Carbidopa with Levodopa	August 25, 2007
Sun Pharma announces USFDA approval to market generic Octreotide injection	August 18, 2007
Investor presentation	July 26, 2007
Notice of extraordinary general meeting on July 28, 2007	July 19, 2007
Sun Pharma to acquire Taro Pharma in a USD 454 million deal	May 21, 2007
Sales growth 30%, profit increased 35%, R&D spend Rs. 2924 million	May 18, 2007
Apportionment of cost between SPIL and SPARC	May 14, 2007
Way forward on demerger	May 14, 2007
Transcript of management presentation on NCE and NDDS	March 26, 2007
Management presentation on NCE and NDDS	March 16, 2007
Announcement of a management presentation on NCE and NDDS	March 12, 2007
Q3 sales up 27%, net profit up 36%	January 29, 2007
3rd Quarter 2006-07 results on 29 Jan 2007, call on 30 Jan at 0930	January 15, 2007

Press Release	Date
Sun Pharma's lead molecule enters Phase II in the US	October 20, 2006
Second quarter results on Oct. 19	October 09, 2006
Conference call transcript- innovative R&D demerger	February 10, 2006
Sun Pharma Board Approves Demerger Of Innovative R&D	February 10, 2006
Board clears demerger proposal	February 09, 2006
Conference call: Demerger of Innovative R&D	February 07, 2006
Sun Pharma's board to meet Jan 30: Q3 results	January 17, 2006
DMF approval for Metaprolol tartrate received	February 14, 2003

Press Release	Date
Sun Pharma closes Able Labs acquisition in the US	December 23, 2005
Sun Pharma H1 results on Oct 28"	October 18, 2005
Sun Pharma shares plans: recent Hungarian and US acquisitions	October 04, 2005
Sun Pharma buys manufacturing facility in Bryan, Ohio	September 14, 2005
Sun Pharma to buy manufacturing site in Hungary	August 10, 2005
Sun Pharma Q1 post results conference call on Thursday July 28 at 11am IST	July 28, 2005
Sun Pharma Board to meet July 27: Q1 results	July 18, 2005
Sun Pharma Board to meet June 6: Q4 results	May 30, 2005
Sun Pharma to donate hostel for medical college	May 12, 2005
Sun Pharma shares guidance for 2005-2006	May 06, 2005
Quarter 4 conference call on April 28 at 10am	April 28, 2005
Q3 result conference Call	January 21, 2005

Press Release	Date
President to inaugurate Sun Pharma's research center	December 07, 2004
Sun Pharma declares interim dividend	November 29, 2004
Sun Pharma completes $275 mill FCCB	November 27, 2004
Sun Pharma launches $225 mill FCCB Issue	November 18, 2004
Sun Pharma board to meet on Oct 21: first half results	October 18, 2004
Sun Pharma to buy 3 US brands for $5.4 mill Entry in brand market in North America	September 23, 2004
Fire in Unit 1 at Panoli	August 06, 2004
Sun Pharma: flood at plant sites	August 04, 2004
Sun Pharma Q1 post results conference call on Monday, August 2 at 11.00 am	August 02, 2004
Sun Pharma announces swap ratio for Phlox Pharma merger	July 31, 2004
Sun Pharma board to meet July 31: Q1 results	July 19, 2004
Sun Pharma to acquire a bulk active company : Phlox Pharma has EDMF approval, UKMCA / USFDA compliant plant	July 06, 2004
Fire put out at Sun Pharma's corporate offices	June 21, 2004
Buyback of 6% cumulative redeemable preference shares	May 27, 2004
Sun Pharma's bulk active and tablet manufacturing factories are cleared by USFDA	May 26, 2004
Letter to the stock exchange for result correction	May 17, 2004
Record date for bonus is May 29	May 06, 2004
No such proposal, says Sun Pharma Bloomberg story titled "Sun Pharma plans to acquire remaining stake in Caraco"	April 23, 2004
Sun Pharma Q4 post results conference call on Thursday April 22, 12 noon	April 22, 2004
1:1 Bonus announced exports jumps 48%; powers profit growth PAT up 21.2%, total income up 20.8%, R&D expense 11.7% of turnover	April 21, 2004
Sun Pharma board to meet April 21: Audited financial results	April 13, 2004
Sun Pharma to raise $350mill, EGM announced	April 08, 2004
Sun Pharma board to meet; to consider issue of convertible debentures	April 02, 2004
Sun Pharma hikes stake in Caraco to 63.14%"	March 13, 2004
Clarification on news items regarding acquisition of HAL	March 09, 2004
Sun Pharma purchases additional stake in Caraco to hold over 60 % equity	February 03, 2004
Mr. Ashwin Dani joins Sun Pharma board	February 02, 2004
Q3 results conf call Jan 28/5pm IST	January 28, 2004
Unaudited Q3 numbers on January 28	January 19, 2004

Press Release	Date
Sun Pharma H1 post results conference call on Wednesday October 22, 11am	October 22, 2003
Sun Pharma to announce unaudited H1 numbers on October 21	October 16, 2003
Sun Pharma to announce unaudited q1 numbers on July 28	July 16, 2003
Sun Pharma conference call after the Q1 results on Monday, July 28	July 16, 2003
Conference call after the Q1 results on Monday, July 28	July 17, 2003
Q4 conf call on May5	May 05, 2003
Sun Pharma to announce audited q4 numbers on May 3	April 25, 2003
DMF approval for Metaprolol tartrate received	February 14, 2003
Q3 conf call announcement for Jan 30	January 30, 2003
Q3 numbers on January 30	January 20, 2003

Press Release	Date
EGM clears resolutions for split, buyback	December 20, 2002
Sun Pharma board proposes buyback plan	October 28, 2002
Q2 results on October 28, 2002	October 21, 2002
Biostudy volunteer in hospital with pneumonia	September 10, 2002
Mr Keki Mistry joins Sun Pharma's board of directors	August 29, 2002
AGM approves bonus preference	August 28, 2002
Conference call after the Q1 unaudited numbers on Monday, July 22	July 22, 2002
Sun Pharma launches anticancer with novel biodegradable microsphere technology product readily available at distribution centers, first time in India	July 16, 2002
Sun Pharma announces Bonus Preference Shares carrying coupon of 6% in ratio of 4 shares of Re 1/- each per 1 equity share held	June 28, 2002
Sun Pharma announces audited numbers, dividend, bonus preference, M J Pharma swap record date	May 31, 2002
Sun Pharmas board to meet: audited accounts, MJ Pharma merger	May 27, 2002
Earnings conference call	April 23, 2002
Offer letter to shareholders-regional stock exchanges delisting	March 30, 2002
Sun Pharma's new plant at Dadra commences operations	March 28, 2002

Press Release	Date
Sun Pharma launches Smoquit	August 10, 2001
Hasmukh Shah joins Sun Pharma board	March 23, 2001
Sun Pharma board announces 1:500 ratio for PDC	February 26, 2001
Board to meet to consider merger of Pradeep Drugs	February 10, 2001
Sun Pharma clarifies on news stories.	January 20, 2001

Press Release	Date
Sun Pharma board to consider merger of export subsidiary	March 31, 2000
Sun Pharma declares 40% second interim dividend	March 18, 2000
Sun Pharma announces bonus	February 01, 2000
Sun Pharma board to consider bonus on Feb 1	January 21, 2000

Press Release	Date
Sun Pharma - Milmet Labs merger	November 26, 1999
Sun Pharma declares 60% interim dividend	November 06, 1999
Sun Pharma to set up new research campus in Chennai	October 25, 1999
CLARIFICATION- No intimation from BIFR	September 11, 1999
CLARIFICATION Chennai Plant	August 18, 1999
BIFR Okays GLOL merger	April 08, 1999

Stories

Sun Pharma is Great Place To Work® Certified™ in 25 countries

We are proud to have earned the Great Place To Work® Certification™ in 25 countries across the globe. The certification was earned by Sun Pharma based on the Trust Index™ Survey by the Great Place To Work® (GPTW) Institute. Over 38,000 employees participated in the global survey.

Sun Pharma’s Dewas Plant Champions Diversity in Manufacturing

In the world of pharmaceutical manufacturing, a domain predominantly associated with men in hard hats and assembly lines, a remarkable transformation has been taking place at Sun’s Dewas plant in India. It’s a tale of breaking the mould and creating a gender diverse team to manage manufacturing blocks.

Sun Pharma Recognized as a Great Place to Work in India

At Sun Pharma, we believe a great team makes a great workplace, and our employees agree. In October 2022, we became Great Place To Work® Certified™ in India, and we were also recognized as one of India’s Best Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022.

Sun Pharma No. 1 Generic Company in PatientView Survey

At Sun, our patients are at the centre of everything we do. We are committed to helping them lead happier and healthier lives. When we see the difference our work makes in people’s lives, it inspires us to do better.